Laquinimod: Phase III amended

Teva and Active said they halted testing of 1.2 and 1.5 mg doses of once-daily oral laquinimod after non-fatal cardiovascular events were observed in the double-blind, placebo-controlled, international Phase II ARPEGGIO and Phase III CONCERTO trials. The DMC for the trials recommended the discontinuation. In both trials, there were no CV events in patients receiving placebo or 0.6 mg laquinimod. Both trials will continue their 0.6 mg arms. ...